May 10, 2019 11:09 AM EDT
News Briefing

Lam­bast­ed by AIDS ac­tivists about Tru­va­da pric­ing, Gilead of­fers CDC drug sup­ply deal; Fi­bro­Gen MACE mis­com­mu­ni­ca­tion leaves in­vestors dis­ori­ent­ed

Natalie Grover

Reporter

→ Chas­tised by AIDS ac­tivists for its pric­ing pol­i­cy on Tru­va­da, Gilead $GILD has agreed to pro­vide to CDC with up to 2 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

Up­dat­ed: J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

A service from the Financial Times